Search This Blog

Wednesday, June 10, 2026

FDA grants RMAT to Cellectis allogeneic CAR-T lasme-cel for relapsed or refractory B-cell ALL

 

FDA grants RMAT designation to Cellectis' CD22-targeting allogeneic CAR-T lasme-cel for relapsed or refractory B-cell ALL

  • RMAT designation is expected to support Cellectis' ongoing pivotal Phase 2 BALLI-01 trial in relapsed or refractory B-ALL.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)